News und Analysen
EQS-News: Evotec presents paradigm shift in biologics at Capital Markets Day
EQS-News: Evotec presents paradigm shift in biologics at Capital Markets Day
EQS-News: AUTO1 Group SE: AUTO1 Group reports strong Q3 revenue growth and makes significant progress towards profitability
EQS-News: AUTO1 Group SE: AUTO1 Group reports strong Q3 revenue growth and makes significant progress towards profitability
Del Webb Breaks Ground on Newest Michigan Community
Del Webb, the nation’s leading builder of active adult communities for those 55 and older, has officially broken ground on its newest community in southeast Michigan, Kensington Ridge by Del Webb
Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222
Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222
CORRECTING and REPLACING Acadia Healthcare Reports Third Quarter 2022 Results
There was an inadvertent error on the supplementary table titled “Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to Adjusted Income Attributable to Acadia Healthcare
EQS-News: Siltronic AG: Verena Stütze appointed as Head of Investor Relations & Communications
EQS-News: Siltronic AG: Verena Stütze appointed as Head of Investor Relations & Communications
EQS-News: Siltronic AG: Verena Stütze appointed as Head of Investor Relations & Communications
EQS-News: Siltronic AG: Verena Stütze appointed as Head of Investor Relations & Communications
EQS-Adhoc: CANCOM SE: 11 percent revenue growth in Q3 2022 but also higher expenses. New revised annual forecast with target corridors published.
EQS-Adhoc: CANCOM SE: 11 percent revenue growth in Q3 2022 but also higher expenses. New revised annual forecast with target corridors published.
EQS-Adhoc: CANCOM SE: 11 percent revenue growth in Q3 2022 but also higher expenses. New revised annual forecast with target corridors published.
EQS-Adhoc: CANCOM SE: 11 percent revenue growth in Q3 2022 but also higher expenses. New revised annual forecast with target corridors published.
EQS-News: SHOP APOTHEKE EUROPE: SOLID AND SUCCESSFUL QUARTER, FULLY IN LINE WITH GUIDANCE. BETTER MARGINS AND CONTINUED MARKET SHARE GAINS.
EQS-News: SHOP APOTHEKE EUROPE: SOLID AND SUCCESSFUL QUARTER, FULLY IN LINE WITH GUIDANCE. BETTER MARGINS AND CONTINUED MARKET SHARE GAINS.
EQS-News: Aurubis AG: Update on cyber attack at Aurubis
EQS-News: Aurubis AG: Update on cyber attack at Aurubis
EQS-News: Evotec, CDP Venture Capital and Angelini Ventures launch translational partnership 'Extend' with leading Italian academic Institutions
EQS-News: Evotec, CDP Venture Capital and Angelini Ventures launch translational partnership 'Extend' with leading Italian academic Institutions
EQS-News: FUCHS PETROLUB SE: Strong third quarter supports nine-month results in a challenging market environment
EQS-News: FUCHS PETROLUB SE: Strong third quarter supports nine-month results in a challenging market environment
EQS-News: Siltronic AG posts strong results for third quarter of 2022
EQS-News: Siltronic AG posts strong results for third quarter of 2022
EQS-News: Siltronic AG posts strong results for third quarter of 2022
EQS-News: Siltronic AG posts strong results for third quarter of 2022
EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
EQS-Adhoc: ProSiebenSat.1 updates full-year outlook 2022 due to development of the macroeconomic environment / Non-cash impairment of assets within the cash-generating unit of NuCom Group
EQS-Adhoc: ProSiebenSat.1 updates full-year outlook 2022 due to development of the macroeconomic environment / Non-cash impairment of assets within the cash-generating unit of NuCom Group
Western Union and NymCard Partner in the UAE
Western Union and NymCard today announced that they have signed a partnership that will enable FinTechs and financial institutions in the United Arab Emirates (the UAE) to offer international money
EQS-News: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
EQS-News: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
EQS-News: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
EQS-News: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
EQS-News: Nemetschek SE: Continued Double-Digit Growth in Q3 2022 Driven by High Demand for Subscription and SaaS
EQS-News: Nemetschek SE: Continued Double-Digit Growth in Q3 2022 Driven by High Demand for Subscription and SaaS
EQS-News: Nemetschek SE: Continued Double-Digit Growth in Q3 2022 Driven by High Demand for Subscription and SaaS
EQS-News: Nemetschek SE: Continued Double-Digit Growth in Q3 2022 Driven by High Demand for Subscription and SaaS
EQS-News: KION Group Results for First Nine Months of 2022 Impacted by Sharp Increase in Project Business Costs in Third Quarter
EQS-News: KION Group Results for First Nine Months of 2022 Impacted by Sharp Increase in Project Business Costs in Third Quarter